- Home
- CZNC vs CTNM Comparison
CZNC vs CTNM Comparison
Compare CZNC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CZNC | CTNM |
|---|---|---|
| Founded | 1864 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.0M | 480.5M |
| IPO Year | 2009 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CZNC | CTNM |
|---|---|---|
| Price | $20.89 | $13.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $23.50 | $19.00 |
| AVG Volume (30 Days) | 26.1K | ★ 262.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 7.64 | 0.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,052.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.02 | $3.35 |
| 52 Week High | $24.12 | $16.33 |
Technical Indicators
Market Signals| Indicator | CZNC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 51.86 |
| Support Level | $19.82 | $11.62 |
| Resistance Level | $22.48 | $16.17 |
| Average True Range (ATR) | 0.52 | 0.94 |
| MACD | -0.23 | 0.11 |
| Stochastic Oscillator | 4.71 | 49.29 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.